Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Lexicon Pharmaceuticals announces publication of preclinical data in the Journal of the Endocrine Society.
December 05, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with...
November 25, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler...
November 11, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Lexicon Pharmaceuticals will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18.
March 05, 2019 09:00 ET | Source: Shareholders Foundation, Inc.

Deadline in Lawsuit for Investors in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced by Shareholders Foundation

SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX). ...